Corticoids+ tocilizumab 8mg/kg/4 weeks (DrugBank: Tocilizumab)
18 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 0 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
40 | Takayasu arteritis | 0 |
41 | Giant cell arteritis | 1 |
42 | Polyarteritis nodosa | 0 |
43 | Microscopic polyangiitis | 0 |
46 | Malignant rheumatoid arthritis | 0 |
50 | Dermatomyositis | 0 |
51 | Scleroderma | 0 |
53 | Sjogren syndrome | 0 |
54 | Adult still disease | 0 |
55 | Relapsing polychondritis | 0 |
56 | Behcet disease | 0 |
86 | Pulmonary arterial hypertension | 0 |
107 | Juvenile idiopathic arthritis [Systemic juvenile idiopathic arthritis (~Mar 2018)] | 0 |
266 | Familial mediterranean fever | 0 |
271 | Ankylosing spondylitis | 0 |
331 | Idiopathic multicentric castleman disease | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01910038 (ClinicalTrials.gov) | November 8, 2013 | 17/7/2013 | Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. | Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. | Giant Cell Arteritis | Drug: corticoids+ tocilizumab 8mg/Kg/4 weeks | Centre Hospitalier Universitaire Dijon | NULL | Completed | 50 Years | N/A | All | 20 | Phase 2 | France |